Trials / Completed
CompletedNCT00357045
Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine
Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine; THE HEPDEP II STUDY
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Portland VA Medical Center · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Objectives: 1. To determine whether paroxetine can prevent major depression in patients with hepatitis C (HCV) who are receiving pegylated-interferon (Peg-IFN). 2. To determine whether paroxetine can prevent subsyndromal increases in depression and anxiety in patients with HCV who are receiving Peg-IFN. 3. To determine whether paroxetine can prevent a significant change in the health related quality of life in patients with HCV who are receiving Peg-IFN. 4. To determine whether paroxetine improves compliance with Peg-IFN therapy for HCV. 5. To determine whether paroxetine enables patients to complete Peg-IFN therapy for HCV who might otherwise require a dose reduction or discontinuation because of neuropsychiatric side effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paroxetine |
Timeline
- First posted
- 2006-07-27
- Last updated
- 2006-07-27
Source: ClinicalTrials.gov record NCT00357045. Inclusion in this directory is not an endorsement.